Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...

In drug development news, FDA granted accelerated approval for Boehringer’s Hernexeos (zongertinib) as a first-line HER2-mutant non-small cell lung cancer treatment in just 44 days, utilizing the ...

Amatera’s approach is “2x faster and 10x more cost-effective” than industry standards for developing new varieties of perennials, it claims.

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell ...

Lucknow: The state govt constituted a Kaushal Connect Cell (KCC) to provide manpower to large industries investing in the ...

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

PHCbi will exhibit LiCellGrow™ at the 25th Congress of the Japanese Society for Regenerative Medicine, March 19-20 at the Kobe International Conference Center and Kobe International Exhibition Center ...

TARPON SPRINGS, Fla., March 6, 2026 - Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 ...

Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; ...

JNARDDC advances indigenous metallurgical technologies to reduce India's import dependence, enhancing quality control and ...